Press release
Arcturus Therapeutics Announces the Formation of its Vaccine Platform Scientific Advisory Board
Renowned experts in virology, infectious disease, vaccine development and public health to support Arcturus’ COVID-19 vaccine program, LUNAR-COV19 Company
About this update from Arcturus Therapeutics Holdings Inc.
[{"type":"text","content":"Renowned experts in virology, infectious disease, vaccine development and public health to support Arcturus’ COVID-19 vaccine program, LUNAR-COV19\n Company remains on track to begin clinical trial for COVID-19 vaccine this summer SAN DIEGO, July 01, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today announced the formation of its Vaccine Platform Scientific Advisory Board (SAB) comprised of world-leading experts in the fields of virology, infectious disease, vaccine development and public health. “We are proud to have such an accomplished and diverse group of scientific, clinical and public policy experts joining our Scientific Advisory Board. The SAB’s expertise will be highly valuable to maximizing the development path and therapeutic potential of the Company’s COVID-19 vaccine program,” said Edward Holmes, M.D., Distinguished Professor of Medicine at the University of California, Vice Chancellor/Dean of Health Sciences Emeritus at the University of California, San Diego and member of Arcturus’ Board of Directors. “Our differentiated self-replicating mRNA-based approach has the potential to require only a single administration at very low doses to result in potent humoral and cellular immunity. I look forward to working closely with our SAB members to bring our promising vaccine approach forward to help address this global public health crisis. Our STARR™ technology is a versatile platform that can be readily adapted to rapidly develop vaccines for a wide range of diseases and with the guidance of our advisors we expect to select additional vaccine candidates for our portfolio,” said Pad Chivukula, Ph.D., Chief Scientific Officer and Chief Operating Officer of Arcturus Therapeutics. Arcturus’ new SAB members: Jeff Colyer, M.D., CEO of Virtus Consultants; former Governor of KansasOoi Eng Eong, Ph.D., BMBS, FRCPath, Professor and Deputy Director of the Emerging Infectious Diseases Programme at the Duke-NUS Medical SchoolFrederick G. Hayden, M.D., FACP, Professor Emeritus of Clinical Virology and Medicine at Virginia University School of MedicinePeter A. Patriarca, M.D., Principal of Immuno-Vax and Senior Aff...